Is VYNE Therapeutics, Inc. overvalued or undervalued?

As of 9 March 2023, the valuation grade for VYNE Therapeutics, Inc. has moved from risky to does not qualify, indicating significant concerns about its financial health. The company appears to be overvalued given its current metrics, particularly with a price to book value of 0.38 and an EV to EBITDA ratio of 0.74. Notably, the return on equity (ROE) stands at a concerning -95.55%, which further supports the notion of overvaluation.
In comparison to its peers, VYNE Therapeutics has a less favorable position, with NanoViricides, Inc. and Mangoceuticals, Inc. also classified as does not qualify, but with EV to EBITDA ratios of -2.0886 and -2.0415, respectively. The company's recent stock performance has been dismal, with a year-to-date return of -72.71%, contrasting sharply with the S&P 500's gain of 2.44%. Overall, these indicators suggest that VYNE Therapeutics is overvalued in the current market environment.